How should I assess and manage a suspected measles case?

Assessment (clinical + public health)

1) Recognise a compatible clinical picture

• Incubation: typically 10–14 days (often quoted ~10 days), followed by a 2–4 day prodrome before rash onset. [1]
• Prodrome: fever, malaise, cough, coryza, conjunctivitis (± diarrhoea). [1]
• Koplik spots (pathognomonic; not always present): small red buccal spots with bluish‑white centres, often opposite molars; appear around 1–2 days before the rash. [1]
• Rash: erythematous maculopapular (morbilliform) rash typically starts on face/forehead/behind ears, then spreads to trunk/limbs over 3–4 days, may become confluent, then fades in order of appearance. [1]

2) Assess infectious period / transmission risk

• Infectious from symptom onset (≈4 days before rash) until 4 days after rash onset. [1]
• Spread is airborne/respiratory droplets and secretions; virus can remain transmissible on surfaces/air for up to ~2 hours. [1]

3) Immediate infection control and notification

• Because of major public health implications, suspected cases require urgent public health action; notify your local Health Protection Team (HPT) and follow UKHSA processes. [1]

4) Laboratory confirmation (don’t rely on clinical diagnosis alone)

• In low-incidence settings, laboratory confirmation is required (clinical diagnosis can be unreliable). [1]
• Testing options include:
  • Oral fluid (OF) is described as the optimal sample for measles surveillance (can test IgM/IgG and measles RNA). In community settings this is usually coordinated via the HPT after notification. [1]
  • If OF not available: send serum for measles IgM (within 6 weeks of onset) and a mouth swab. [1]

Management

1) Individual (clinical) management

• Uncomplicated measles is usually self-limiting; treatment is mainly supportive:
  • antipyretics (e.g., paracetamol or ibuprofen) and adequate fluids. [1]
  • advise patient to remain at home to limit spread. [1]
• Monitor carefully for complications and consider hospitalisation if these develop (clinical judgement based on severity and complications). [1]
• Vitamin A: noted as sometimes used to reduce risk of complications in confirmed measles (typically guided by local policy/specialist/public health advice). [1]

2) Isolation / exclusion advice

• Advise exclusion from school/work and minimising contact with vulnerable/susceptible people; infectiousness lasts to 4 days after rash onset. [1]

Post-exposure prophylaxis (contacts) — in conjunction with HPT

• MMR vaccination for susceptible contacts (≥6 months old), ideally within 72 hours of exposure. [1]
• Human normal immunoglobulin may be considered within 5 days of exposure for:
  • immunocompromised children/adults
  • potentially pregnant susceptible contacts (offered selectively because most are immune). [1]

Practical workflow (primary/acute care)

1. Suspect measles based on prodrome + typical rash pattern (check for Koplik spots). [1]
2. Isolate and minimise exposure (airborne transmission; high infectivity). [1]
3. Notify local HPT urgently and follow UKHSA guidance pathways. [1]
4. Arrange laboratory confirmation (prefer oral fluid via HPT; otherwise serum IgM + mouth swab). [1]
5. Provide supportive care, counsel on exclusion, and escalate/admit if complications/severe illness. [1]
6. Coordinate contact tracing and PEP (MMR within 72h; immunoglobulin within 5 days for selected high-risk contacts) with HPT. [1]